Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423334 | 0.87 | KDM4E (0.50) | KDM4EGAAALDH1A1POLBGRIN1 | |
| SCHEMBL2898509 | 0.87 | KDM4E (0.50) | KDM4EGAAALDH1A1POLBGRIN1 | |
| SCHEMBL29415468 | 0.81 | KDM4E (0.63) | KDM4EGAAALDH1A1POLBHRH3 | |
| SCHEMBL2806050 | 0.81 | KDM4E (0.63) | KDM4EGAAALDH1A1POLBHRH3 | |
| SCHEMBL10969986 | 0.80 | KDM4E (0.66) | KDM4EGAAALDH1A1POLBFLT3 | |
| SCHEMBL2310250 | 0.80 | F7 (0.63) | KDM4EGAAALDH1A1POLBGRIN1 | |
| SCHEMBL8500109 | 0.80 | KDM4E (0.63) | KDM4EGAAALDH1A1POLBFLT3 | |
| SCHEMBL11142199 | 0.80 | KDM4E (0.61) | KDM4EGAAALDH1A1POLBMEN1 | |
| SCHEMBL2311400 | 0.78 | GABRA1 (0.56) | KDM4EGAAALDH1A1POLBMEN1 | |
| SCHEMBL30305109 | 0.78 | GABRA1 (0.56) | KDM4EGAAALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705297-A1 | SMALL MOLECULE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024229205-A1 | SMALL MOLECULE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | WO | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8288549-B2 | Glycine B antagonist | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | HENRICH MARKUS | 2011-08-04 | — | — | US | disclosed |
| EP-2350014-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010037533-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-04-08 | — | — | WO | disclosed |
| EP-1628990-B1 | NOVEL 14 AND 15 MEMBERED RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009128262-A1 | QUINOLONE DERIVATIVE AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2009-10-22 | — | — | WO | disclosed |
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| EP-1628990-A1 | NOVEL 14 AND 15 MEMBERED RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-1628988-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-1625137-A1 | MACROLIDES SUBSTITUTED AT THE 4''-POSITION | GLAXO GROUP LIMITED (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101585-A1 | MACROLIDES SUBSTITUDED AT THE 4'-POSITION | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101586-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101588-A1 | NOVEL 14 AND 15 MEMBERED RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101584-A1 | MACROLIDES SUBSTITUTED AT THE 3-POSITION HAVING ANTIMICROBIAL ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| US-4710507-A | Quinolone inotropic agents | PFIZER INC. (US) | 1987-12-01 | — | — | US | disclosed |
| CN-85100796-A | The preparation method of qualone derivative | — | 1986-10-01 | — | — | CN | disclosed |
| EP-0148623-A2 | Quinolone inotropic agents | Pfizer Limited (GB) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190342-A1 | GLYCINE B ANTAGONIST | GRIN2B, GLRB, GRIN2A | KDM4E 3958/4885GAA 707/4885ALDH1A1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.